The purpose of this study is to determine the recommended dose (RD) for further phase II
studies, of the Galectin-1 inhibitor OTX008 given subcutaneously in patients with advanced
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01724320
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Signed informed consent prior to beginning protocol specific screening procedures. Patients registered in this trial must be treated and followed at the participating centers. Patients should receive the study treatment within 7 days after registration
Histologically proven malignant solid tumor
Patients having failed all standard therapies, or for whom standard therapies are deemed ineffective or contra-indicated.
Patients aged > 18 years.
ECOG performance status (PS) of 0 to 1
Off previous systemic therapy (except LH-RH agonist therapy started > 2 months prior to study entry that could be continued) , radiation therapy, or surgery for at least 30 days prior to first study treatment administration (45 days for bicalutamide).
Recovery from the toxic effects of prior treatment to NCIC-CTC grade < 1, except alopecia
Adequate bone marrow function including: Neutrophils >= 1.5 x 10E9 /L; platelets >= 100 x 10E9 /L, Hb > 8g/dL without transfusion.
Creatinine clearance >= 60 mL/min (Cockroft & Gault formula, or MDRD formula for patients aged > 65 years).
Adequate LFTs: Total bilirubin < 1 x the institutional upper normal limits (UNL); ALAT/ASAT >= 3 x UNL (or >= 5 x UNL in case of liver metastases).
Serum albumin > 28g/L.
Availability of the last tumor imaging within 6 months prior to baseline tumor imaging
Availability of archived pathology specimen (paraffin-embedded block) from the tumor
History of prior malignancy other than those previously treated with a curative intent more than 5 years ago and without relapse (any tumor) or basal cell skin cancer, in situ cervical cancer, superficial bladder cancer, or high grade intestinal polyps treated adequately, regardless of the disease-free interval.
Pregnant or lactating women or women of childbearing potential not using adequate contraception. Male patients not using adequate contraception.
Tumor sites that necessitate immediate intervention (supportive care, surgery or radiation therapy) such as symptomatic brain or leptomeningeal tumor, spinal cord compression, other compressive tumor masses, painful bone metastasis, bone fracture, etc…
Other serious illness or medical conditions, which, in the investigator's opinion could jeopardize patient's safety or hamper understanding of the study by the patient, patient's compliance to study treatment, or interpretation of study results. These conditions include (but are not restricted to):
Congestive heart failure or angina pectoris not medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmias.
Existence of significant neurologic or psychiatric disorders impairing the ability to obtain consent.
Concurrent treatment with other experimental therapies or participation in another clinical trial within 30 days prior to first study treatment administration.
Concurrent treatment with any other anticancer therapy (except LH-RH agonist therapy initiated > 2 months prior to study entry).
All locations for NCT01724320
Institut Jules Bordet
Brussels, Belgium, 1000
Put me in touch!
Hopital Beaujon - AP-HP
Clichy, France, 92110
Put me in touch!
Institut Claudius Regaud
Toulouse, France, 31052
Put me in touch!
View full eligibility
Tris trial is registered with FDA with number: NCT01724320. The sponsor of the trial is Oncoethix GmbH and it is looking for 20 volunteers for the current phase.
Official trial title: A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.